Zytux (rituximab biosimilar) / AryoGen Pharmed - LARVOL DELTA

Long-Term Adverse Events of Rituximab in Multiple Sclerosis Patients, Isfahan, Iran. (PubMed, Int J Prev Med) - "Around 39.4% of the patients had at least one side effect, most of which were minor infections of the urinary and respiratory tract, all mild in nature. RTX treatment is well-tolerated and safe, with a minor risk of mild infusion reactions and minor side effects for MS patients."

Adverse events • Journal • CNS Disorders • Infectious Disease • Multiple Sclerosis

Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. (PubMed, Hematol Rep) - "Regarding safety profile, Zytux™ demonstrated similar adverse reactions in comparison to MabThera® (Roche Spa). Moreover, the overall response rate in both groups was 85% with complete response achieved in 35% and partial response in remaining 50%.This study concluded that the early results of use of Zytux™ in NHL and CLL were not inferior to reference drug MabThera® in contrast it was comparable and even better in term of safety and efficacy."

Clinical • Journal • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Evaluating the efficacy and safety of Zytux (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study. (PubMed, Mult Scler Relat Disord) - "The observed results revealed that the Zytux™ could have a positive and significant effect on all types of MS."

Clinical • Journal • Observational data • CNS Disorders • Infectious Disease • Multiple Sclerosis • Nephrology • Pain • Pneumonia • Respiratory Diseases